Patents by Inventor Saskia Maria Brachmann

Saskia Maria Brachmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR FOR THE TREATMENT OF CANCERS
    Publication number: 20240082218
    Abstract: It relates to a pharmaceutical combination comprising a KRAS G12C inhibitor, in particular 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro [3.3] heptan-2-yl} prop-2-en-1-one (Compound A) and one or more therapeutically active agents selected from a SHP2 inhibitor (e.g. TNO155) and a PD-1 inhibitor, pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutated.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 14, 2024
    Inventors: Vasileios ASKOXYLAKIS, Saskia Maria BRACHMANN, Simona COTESTA, Xiaoming CUI, Jeffrey ENGELMAN, Anna FARAGO, Marc GERSPACHER, Diana GRAUS PORTA, Catherine LEBLANC, Edwige Liliane Jeanne LORTHIOIS, Bo LIU, Rainer MACHAUER, Robert MAH, Christophe MURA, Pascal RIGOLLIER, Nadine SCHNEIDER, Stefan STUTZ, Andrea Helga Emmi VAUPEL, Nicolas WARIN, Andreas WEISS, Rainer WILCKEN, Padmaja YERRAMILLI-RAO
  • PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND A KRASG12C INHIBITOR
    Publication number: 20220152026
    Abstract: The present invention relates to a pharmaceutical combination comprising TNO155 and a KRASG12C inhibitor; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in a SHP2 inhibitor combined with KRASG12C inhibition is beneficial in, for example, the treatment of cancers.
    Type: Application
    Filed: February 10, 2020
    Publication date: May 19, 2022
    Inventors: Saskia Maria Brachmann, Danilo Maddalo, Anirudh Cadapa Prahallad
  • Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
    Publication number: 20200022967
    Abstract: The use of compounds of formula (I) in the treatment of Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds and pharmaceutical preparations for the treatment of said diseases comprising said compounds alone or in combination, especially with an EGFR modulator.
    Type: Application
    Filed: September 17, 2019
    Publication date: January 23, 2020
    Inventors: Saskia Maria BRACHMANN, Christine FRITSCH, Saveur-Michel MAIRA, Christian Renee SCHNELL, Carlos Garcia-Echeverria
  • Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
    Publication number: 20180325883
    Abstract: The use of compounds of formula (I) in the treatment of Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds and pharmaceutical preparations for the treatment of said diseases comprising said compounds alone or in combination, especially with an EGFR modulator.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 15, 2018
    Inventors: Saskia Maria Brachmann, Christine Fritsch, Sauveur-Michel Maira, Christian Schnell, Carlos Garcia-Echeverria
  • Imidazoquinolines as dual lipid kinase and mTOR inhibitors
    Patent number: 9370508
    Abstract: The invention relates to the use of compounds of formula (I) in the treatment of mammalian target of rapamycin (mTOR) kinase dependent diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of said diseases.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: June 21, 2016
    Assignee: NOVARTIS AG
    Inventors: Carlos Garcia-Echeverria, Paul Leslie Nicklin, Leon Murphy, Sauveur-Michel Maira, Peter Finan, Christine Fritsch, Saskia Maria Brachmann
  • Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
    Publication number: 20150250778
    Abstract: The use of compounds of formula (I) in the treatment of Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds and pharmaceutical preparations for the treatment of said diseases comprising said compounds alone or in combination, especially with an EGFR modulator.
    Type: Application
    Filed: May 26, 2015
    Publication date: September 10, 2015
    Inventors: Saskia Maria Brachmann, Christine Fritsch, Sauveur-Michel Maira, Christian Schnell, Carlos Garcia-Echeverria
  • Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
    Publication number: 20130209461
    Abstract: A method for treating an Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members comprising administering a therapeutically effective amount of a compound of formula (I) alone or in combination with an EGFR modulator, to a warm-blooded animal in need thereof; combinations comprising the compound of formula (I) and an EGFR modulator for the treatment of said diseases; and pharmaceutical preparations for the treatment of said diseases comprising the compound of formula (I), alone or in combination with an EGFR modulator.
    Type: Application
    Filed: November 7, 2011
    Publication date: August 15, 2013
    Applicant: NOVARTIS AG
    Inventors: Saskia Maria Brachmann, Christine Fritsch, Sauveur-Michel Maira, Christian Rene Schnell, Carlos Garcia-Echeverria
  • IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS
    Publication number: 20100105696
    Abstract: The invention relates to the use of compounds of formula (I) in the treatment of mammalian target of rapamycin (mTOR) kinase dependent diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of said diseases.
    Type: Application
    Filed: February 19, 2008
    Publication date: April 29, 2010
    Applicant: NOVARTIS AG
    Inventors: Carlos Garcia-Echeverria, Paul Leslie Nicklin, Leon Murphy, Sauveur-Michel Maira, Peter Finan, Christine Fritsch, Saskia Maria Brachmann